Similarly, in a mixed-tumor survivorship cohort more than two years after starting PD-1/PD-L1 therapy, global HRQL scores were approximately equal to population norms, but neurocognitive symptoms, anxiety, depression, and sexual health concerns were still prevalent in a meaningful minority of patients [17]. This evidence concerns the gene CD274 and neoplasm.